GSK PLC ADR GSK
News
GSK Says Individual Plaintiff in Latest Zantac Case Dropped Claim
GSK Vaccine to Prevent Respiratory-Tract Disease Approved for Expanded Use
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
GSK Buys Elsie Biotechnologies for Up to $50 Million
GSK Down Nearly 9%, on Pace for Largest Percent Decrease Since March 2020 — Data Talk
Trending: GSK Shares Tumble on Zantac's Legal Setback
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
GSK Shares Plunge After Delaware Ruling Allowing Jury Trials for Zantac Case — Update
GSK Shares Plunge After Delaware Ruling on Zantac
GSK shares tumble by most in two years after Zantac ruling
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
Moderna wins second product approval with RSV vaccine
AstraZeneca started at buy at Goldman, which rates GSK a neutral
Who will be the winner in Rishi Sunak's snap U.K. election?
GSK Says Illinois Jury Finds Heartburn Drug Zantac Not Liable for Plaintiff's Cancer
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia
Potential blockbuster asthma drug met goals in trials, GSK says
GSK's Potential Blockbuster Asthma Drug Shows Promise in Latest Trial — 2nd Update
GSK Potential Blockbuster Asthma Drug Shows Promise in Latest Trial — Update